Biotech Values

[RNsidersbuying]

SLRN 2.85 - getting clobbered in afterhours on what I view as a favorable report?

The Company previously announced it held an end of Phase 2 meeting with the United States Food and Drug Administration and gained alignment on the proposed LONGITUDE-1 and LONGITUDE-2 Phase 3 trial designs. The Company expects to initiate the Phase 3 LONGITUDE program in the first quarter of 2025 and expects topline data from the trial in the second half of 2026.

https://capedge.com/filing/1962918/0001962918-25-000003/SLRN-8K

With approx. $5 cash-per-share, the risk here appears extremely low?